Baltimore, July 19, 2010 -- Noxilizer, Inc., a developer of next generation gas sterilization
technology for hospitals and life science companies, announced the appointment of Lawrence
Bruder as President & Chief Executive Officer.
“Larry brings over 25 years of leadership and operational experience in large and small life
science companies. His successful track record in achieving value creating milestones, attracting
investors and leading venture-backed companies made him an extremely attractive candidate,”
said Lars Hanan, member, Noxilizer Board of Directors and Co-founder and Managing Partner at
BroadOak Capital Partners.
Larry’s professional experience includes leadership positions at: Becton Dickinson, Applied
Biosystems, Leica, Olympus, and Guava Technologies. Most recently he was President and CEO
of venture-backed Guava Technologies, which was sold to Millipore Biosciences in 2009. Most
of his experience prior to Guava was at Becton Dickinson, where he held a number of significant
operational and leadership positions over a 10-year period. His responsibilities in both
companies included the clinical and regulatory aspects of 510(k) submittals to the FDA for
medical devices, significant commercial interaction with pharmaceutical companies, and high
level business development transactional activity; all of these being a critical part of Noxilizer’s
“I’m very excited to join the team at Noxilizer, as the core NO2 sterilant technology will enable
gentle, safe but effective low temperature sterilization of sensitive medical devices, such as prefilled
syringes, bioresorbable polymers and flexible endoscopes. The sterilization of these
devices represents a huge global market opportunity for Noxilizer and I look forward to
commercializing this capability within the hospital and life science marketplace, “said Larry
Mr. Bruder holds a BS from Rochester Institute of Technology and Master of Management in
Marketing & Economics from the Kellogg Graduate School at Northwestern University.
Noxilizer is pioneering the development of a unique and superior sterilization technology that will
revolutionize two major sterilization markets — hospitals and life science manufacturing. In hospitals,
Noxilizer is developing a system especially for the sensitive high-tech equipment increasingly used in
minimally invasive surgical procedures. In the life science market, the development of next generation
therapies and medical devices is constrained by current sterilization technologies. Noxilizer’s roomtemperature
system has shown great potential to be an enabling technology for a wide range of products,
including antibodies, proteins, drug-device combination products, pre-filled syringes, bioresorbable
polymers, nanoparticles and implants.
Noxilizer is committed to providing innovative solutions for healthcare professionals and their patients.
The company was founded in 2004 and is privately held. Noxilizer is located at the University of
Maryland Baltimore County Technology Center in Baltimore, MD.
For more information, please contact:
Maura O. Kahn
Vice President Business Development & Marketing